NCT07187570 RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
| NCT ID | NCT07187570 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Region Stockholm |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,600 participants |
| Start Date | 2025-06-03 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 1,600 participants in total. It began in 2025-06-03 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation? Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation. Persons with atrial fibrillation who are planned for an electric cardioversion will: * Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days
Eligibility Criteria
Inclusion Criteria: * Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date. * Age ≥ 55 years. * Provided written informed consent. Exclusion Criteria: * Current treatment with an SGLT2 inhibitor. * Prior/current diagnosis of heart failure. * Type 1 diabetes mellitus. * Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2. * Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days). * Contraindications to SGLT2 inhibitors. * Any condition or circumstance in which the patient should not participate in the study according to the study investigator.
Contact & Investigator
Karolina Szummer, MD PhD
PRINCIPAL INVESTIGATOR
Karolinska Institutet
Frequently Asked Questions
Who can join the NCT07187570 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07187570 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 1,600 participants.
Is NCT07187570 currently recruiting?
Yes, NCT07187570 is actively recruiting participants. Contact the research team at karolina.szummer@regionstockholm.se for enrollment information.
Where is the NCT07187570 trial being conducted?
This trial is being conducted at Linköping, Sweden, Örebro, Sweden, Stockholm, Sweden, Stockholm, Sweden and 3 additional locations.
Who is sponsoring the NCT07187570 clinical trial?
NCT07187570 is sponsored by Region Stockholm. The principal investigator is Karolina Szummer, MD PhD at Karolinska Institutet. The trial plans to enroll 1,600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.